Home  >  TopNews
Eppen_Protein_LoBind_Nov26
you can get e-magazine links on WhatsApp. Click here
Policy & Regulations + Font Resize -

Industry seeks phased trade margin rationalisation to protect MSMEs & ensure affordable medicines

Shardul Nautiyal, Mumbai
Tuesday, November 3, 2026, 08:00 Hrs  [IST]

The pharmaceutical industry associations have called for a phased and carefully calibrated implementation of Trade Margin Rationalisation (TMR), urging the government to balance affordable medicine prices with the financial sustainability of manufacturers, distributors and retailers.

The industry has proposed limiting the initial rollout to high-value, non-scheduled formulations, providing advance notice of regulatory changes and exempting critical medicines, government tenders and patient assistance programmes to prevent disruptions across the pharmaceutical supply chain.

The recommendations come amid growing debate over the proposed expansion of TMR beyond the cancer medicines segment, where a pilot exercise demonstrated the potential of margin rationalisation to reduce prices for patients. Industry stakeholders, however, believe that extending the mechanism across a wider range of pharmaceutical products requires a comprehensive assessment of existing trade structures, pricing practices and the economic implications for different categories of businesses.

The issue has also been raised by pharmaceutical representatives of Laghu Udyog Bharati (LUB), an RSS-affiliated, not-for-profit pan-India organisation established in 1994 to empower micro and small enterprises. LUB's pharma representatives have also been following with the Department of Pharmaceuticals (DoP) and discussed several important industry concerns, including TMR, extension of the Revised Schedule M compliance timeline, hurdles relating to Revised PTUS and the formation of a Drug Tribunal Board.

During the representations to the government, LUB Pharma proposed the concept of "One Nation-One Molecule-One MRP", advocating that the top 100 pharmaceutical companies should market their generic brands under the respective molecule names at affordable maximum retail prices (MRPs). The proposal is intended to improve price transparency, reduce the multiplicity of prices for the same molecule and make medicines more affordable for patients. It also reflects the concerns of smaller pharmaceutical enterprises over the pricing practices and competitive pressures in the branded generic market.

Separately, leading pharmaceutical industry associations have submitted recommendations seeking a more predictable and balanced TMR framework. They have cautioned that indiscriminate application of margin controls could affect market access, disrupt distribution channels and weaken micro, small and medium enterprises (MSMEs), which have limited financial capacity to absorb sudden changes in trade margins.

One of the principal recommendations is to introduce TMR in phases, beginning with high-value, non-scheduled formulations rather than extending it immediately across the entire pharmaceutical market. The industry has also sought prospective implementation, restricting the applicability of revised margins to batches manufactured after the date of notification. Companies should receive three to six months' advance notice of the guidelines to enable them to revise pricing arrangements, commercial agreements and distribution systems.

Industry associations have further recommended that medicines covered under Para 19 of the Drug Price Control Order (DPCO), which are considered critical to public health, should remain outside the TMR framework. Government tender supplies and patient assistance programmes should also be exempted, considering their distinct procurement arrangements, pricing structures and patient-support objectives.

On price revisions, the industry has recommended adherence to Para 20 of the DPCO, under which revisions should be calculated on the basis of the average of the preceding 12 months. According to the associations, this would provide a more realistic basis for adjustments and prevent abrupt financial implications for manufacturers and wholesalers.

The industry's concerns are also supported by differences in trade margins across traditional retail, organised retail and e-pharmacy channels. An illustrative comparison of branded generic medicines shows that in the traditional retail model, a product with a cost-and-freight (C&F) price of Rs. 70 moves through the wholesaler at Rs. 72 and retailer at Rs. 80, ultimately reaching consumers at an MRP of Rs.100. The corresponding margins are approximately 3 per cent for the C&F agent, 10 per cent for the wholesaler and 20 per cent for the retailer.

In organised retail, the same illustrative distribution structure results in a consumer price of Rs. 90, with the retailer's margin reduced to 12.5 per cent. In the e-pharmacy model, the consumer price falls further to Rs.85, with an indicated retailer margin of 16.5 per cent.

Trade generics present a substantially different pricing structure. These off-patent medicines, marketed under their chemical names rather than established brand names, have a significantly lower distribution cost in the illustrative comparison. A C&F price of Rs. 15 moves to Rs. 15.30 at the generic stockist level and approximately Rs. 17 at the retail stage, with the comparison indicating a 500 per cent retailer margin.

These differences underline the complexity of introducing a uniform margin-control mechanism across pharmaceutical distribution channels. While organised retail and e-pharmacies are increasingly competing through lower consumer prices, traditional retailers and smaller distributors face different operating costs and commercial constraints.

The pharmaceutical industry's central argument is that TMR should not be viewed merely as a price-control instrument but as a broader supply-chain reform requiring careful regulatory design. A future-ready DPCO framework, stakeholders believe, must protect patients from excessive medicine prices while ensuring that smaller manufacturers, distributors and retailers remain economically viable.

The government is therefore being urged to consider the industry's recommendations before expanding TMR, with the objective of ensuring that affordability measures do not inadvertently affect medicine availability, competition and the participation of MSMEs in India's pharmaceutical market.

 

*POST YOUR COMMENT
Comments
* Name :     
* Email :    
  Website :  
   
     
 
API_China2026
Copyright © 2024 Saffron Media Pvt. Ltd | twitter
 
linkedin
 
 
linkedin
 
instagram